Healthcare provider profile · identity verified

Michael Flynn

Family Practice · BOURNE, MA · NPI 1922503945

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	435	127
Lisinopril	Lisinopril	211	64
Levothyroxine Sodium	Levothyroxine Sodium	193	62
Losartan Potassium	Losartan Potassium	190	54
Simvastatin	Simvastatin	137	40
Amlodipine Besylate	Amlodipine Besylate	127	40
Omeprazole	Omeprazole	127	41
Hydrochlorothiazide	Hydrochlorothiazide	112	32
Metoprolol Succinate	Metoprolol Succinate	94	26
Rosuvastatin Calcium	Rosuvastatin Calcium	92	26
Metformin Hcl	Metformin Hcl	89	24
Pantoprazole Sodium	Pantoprazole Sodium	70	23
Metformin Hcl Er	Metformin Hcl	64	19
Lorazepam	Lorazepam	62	16
Tamsulosin Hcl	Tamsulosin Hcl	58	19
Zolpidem Tartrate	Zolpidem Tartrate	58	16
Trazodone Hcl	Trazodone Hcl	57	22
Sertraline Hcl	Sertraline Hcl	55	18
Tramadol Hcl	Tramadol Hcl	50	12
Allopurinol	Allopurinol	49	15
Albuterol Sulfate Hfa	Albuterol Sulfate	48	18
Furosemide	Furosemide	47	14
Escitalopram Oxalate	Escitalopram Oxalate	44	16
Pravastatin Sodium	Pravastatin Sodium	44	18
Gabapentin	Gabapentin	43	16
Eliquis	Apixaban	41	15
Synthroid	Levothyroxine Sodium	40	11
Alprazolam	Alprazolam	39	suppressed
Famotidine	Famotidine	39	12
Sumatriptan Succinate	Sumatriptan Succinate	39	suppressed
Mounjaro	Tirzepatide	37	suppressed
Atenolol	Atenolol	36	12
Fluticasone Propionate	Fluticasone Propionate	36	14
Ozempic	Semaglutide	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Finasteride	Finasteride	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	12
Donepezil Hcl	Donepezil Hcl	29	suppressed
Clonazepam	Clonazepam	28	suppressed
Arnuity Ellipta	Fluticasone Furoate	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	16
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Jardiance	Empagliflozin	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Glipizide	Glipizide	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Midodrine Hcl	Midodrine Hcl	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Azithromycin	Azithromycin	18	17
Buspirone Hcl	Buspirone Hcl	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Prednisone	Prednisone	18	16
Valsartan	Valsartan	18	suppressed
Glipizide Er	Glipizide	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	15
Ondansetron Odt	Ondansetron	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	15
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Temazepam	Temazepam	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Nystatin	Nystatin	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Wegovy	Semaglutide	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Triazolam	Triazolam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error